[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581811":3},{"organization":4,"outcomesModule":7,"designInfo":62,"detailedDescription":21,"studyPopulation":21,"armGroups":69,"interventions":87,"overallOfficials":21,"centralContacts":117,"locations":126,"responsibleParty":433,"collaborators":21,"id":435,"slug":436,"hasResults":437,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":21,"eligibilityCriteria":441,"healthyVolunteers":442,"sex":443,"minAge":444,"maxAge":445,"enrollmentInfo":446,"targetDuration":21,"studyType":449,"phases":450,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":129,"whyStopped":21,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":470},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":26,"otherOutcomes":21},[9,13,16,19,22,24],{"measure":10,"description":11,"timeFrame":12},"Percentage of participants with seroresponse to Varicella Zoster Virus (VZV) anti- glycoprotein E (gE) Immunoglobulin (IgG)","The seroresponse rate is defined as the percentage of participants for whom the post-vaccination Day 43 anti VZV gE IgG concentration is above the seroresponse threshold.","At Day 43",{"measure":14,"description":15,"timeFrame":12},"Geometric Mean Concentration (GMC) of anti-VZV gE IgG","Concentrations of anti-VZV gE IgG are presented as GMC and expressed in milli-international units per milliliter (mIU\u002FmL) for each group.",{"measure":17,"description":18,"timeFrame":12},"Percentage of participants with seroresponse to MMR antigens","The seroresponse rate is defined as the percentage of participants for whom the post-vaccination Day 43 anti-measles, mumps, and rubella antibody concentrations are above the seroresponse threshold.",{"measure":20,"description":21,"timeFrame":12},"GMC of Anti-measles antibodies",null,{"measure":23,"description":21,"timeFrame":12},"GMC of Anti-mumps antibodies",{"measure":25,"description":21,"timeFrame":12},"GMC of Anti-rubella antibodies",[27,29,31,35,38,42,46,50,52,55,59],{"measure":28,"description":21,"timeFrame":12},"Percentage of participants with seroresponse to demonstrate an acceptable immune response for IM administration of MMR vaccine",{"measure":30,"description":21,"timeFrame":12},"Percentage of participants with seroresponse to MMR antigens with a reduced non-inferiority margin",{"measure":32,"description":33,"timeFrame":34},"Percentage of participants reporting each solicited administration site events post-dose of investigational VNS vaccine or VV administration","Solicited administration site events include injection site redness, pain, and swelling.","Day 1 (post-dose) to Day 4",{"measure":36,"description":37,"timeFrame":34},"Percentage of participants reporting each solicited administration site events post-dose of MMR vaccine administration","Solicited administration site events include injection site redness, pain and swelling.",{"measure":39,"description":40,"timeFrame":41},"Percentage of participants reporting each solicited systemic events post-dose of study interventions administration","Solicited systemic events include drowsiness, loss of appetite and irritability.","Day 1 (post-dose) to Day 15",{"measure":43,"description":44,"timeFrame":45},"Percentage of participants reporting each solicited systemic event in terms of fever post-dose of study interventions administration","Fever is defined as temperature greater than or equal (\\>=) 38.0 degrees Celsius (°C) regardless of the location of measurement (the preferred location for measuring temperature is the axilla).","Day 1 (post-dose) to Day 22",{"measure":47,"description":48,"timeFrame":49},"Percentage of participants reporting each solicited administration site events post-dose of study interventions administration","Solicited administration site events include injection site varicella-like rash.","Day 1 (post-dose) to Day 43",{"measure":39,"description":51,"timeFrame":49},"Solicited systemic events includes varicella-like rash (non-injection site), measles\u002Frubella-like rash, and general rash (not varicella like and not measles\u002Frubella-like).",{"measure":53,"description":54,"timeFrame":49},"Percentage of participants reporting unsolicited Adverse Events (AEs) post-dose of study interventions administration","Unsolicited AEs include any AE reported in addition to solicited events during the study, or any \"solicited\" symptoms with onset outside of the specified period of follow-up for solicited symptoms, are assessed for each group after the administration of all vaccines. Unsolicited AEs include nonserious and serious AEs.",{"measure":56,"description":57,"timeFrame":58},"Percentage of participants reporting medically attended AEs (MAAE) post-dose of study interventions administration","A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to\u002Fby a healthcare professional.","Day 1 (post-dose) to Day 181 (Study end)",{"measure":60,"description":61,"timeFrame":58},"Percentage of participants reporting Serious AEs (SAEs) post-dose of study interventions administration","A SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability\u002Fincapacity, or other situations that are considered serious per medical or scientific judgment.",{"allocation":63,"interventionModel":64,"interventionModelDescription":21,"primaryPurpose":65,"observationalModel":21,"timePerspective":21,"maskingInfo":66},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":67,"maskingDescription":68,"whoMasked":21},"NONE","This is an Open Label study.",[70,81],{"label":71,"type":72,"description":73,"interventionNames":74},"VNS+ MMR Vaccine","EXPERIMENTAL","Participants receive 1 dose of the candidate varicella vaccine (VNS vaccine), 1 dose of a measles, mumps, and rubella (MMR) vaccine, 1 dose of a hepatitis A virus (HAV vaccine), and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.",[75,76,77,78,79,80],"Biological: Candidate varicella vaccine","Biological: MMR vaccine","Biological: Hepatitis A vaccine","Biological: PCV (pneumococcal conjugate vaccine) 13","Biological: PCV 20","Biological: Vaxneuvance",{"label":82,"type":83,"description":84,"interventionNames":85},"VV+MMR Vaccine","ACTIVE_COMPARATOR","Participants receive 1 dose of a Marketed varicella vaccine (VV), 1 dose of a MMR vaccine, 1 dose of a HAV vaccine, and 1 dose of PCV (either PCV 13 or Vaxneuvance or PCV 20) on Day 1.",[86,76,77,78,79,80],"Biological: Marketed varicella vaccine",[88,93,97,101,105,109,113],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":21},"BIOLOGICAL","Candidate varicella vaccine","Investigational varicella vaccine administered intramuscularly.",[71],{"type":89,"name":94,"description":95,"armGroupLabels":96,"otherNames":21},"Marketed varicella vaccine","Marketed varicella vaccine administered subcutaneously.",[82],{"type":89,"name":98,"description":99,"armGroupLabels":100,"otherNames":21},"MMR vaccine","MMR vaccine administered subcutaneously or intramuscularly.",[71,82],{"type":89,"name":102,"description":103,"armGroupLabels":104,"otherNames":21},"Hepatitis A vaccine","Hepatitis A vaccine co-administered intramuscularly.",[71,82],{"type":89,"name":106,"description":107,"armGroupLabels":108,"otherNames":21},"PCV (pneumococcal conjugate vaccine) 13","The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.",[71,82],{"type":89,"name":110,"description":111,"armGroupLabels":112,"otherNames":21},"PCV 20","The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.",[71,82],{"type":89,"name":114,"description":115,"armGroupLabels":116,"otherNames":21},"Vaxneuvance","The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.",[71,82],[118,123],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":124,"role":120,"phone":125,"phoneExt":21,"email":122},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[127,149,163,176,190,203,216,230,244,258,271,284,297,311,326,341,352,362,375,390,405,418],{"facility":128,"status":129,"city":130,"state":131,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":140,"contacts":141},"GSK Investigational Site","RECRUITING","Tucson","Arizona","85704","United States","US",{"type":136,"coordinates":137},"Point",[138,139],-110.92648,32.22174,{"lat":139,"lon":138},[142,143,146],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":147,"role":148,"phone":21,"phoneExt":21,"email":21},"Dena Petersen","PRINCIPAL_INVESTIGATOR",{"facility":128,"status":129,"city":150,"state":151,"zip":152,"country":133,"countryCode":134,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Huntington Park","California","90255",{"type":136,"coordinates":154},[155,156],-118.22507,33.98168,{"lat":156,"lon":155},[159,160,161],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":162,"role":148,"phone":21,"phoneExt":21,"email":21},"Albert Nassir",{"facility":128,"status":129,"city":164,"state":151,"zip":165,"country":133,"countryCode":134,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Sherman Oaks","91403",{"type":136,"coordinates":167},[168,169],-118.44925,34.15112,{"lat":169,"lon":168},[172,173,174],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":175,"role":148,"phone":21,"phoneExt":21,"email":21},"Dmitriy Romanenko",{"facility":128,"status":129,"city":177,"state":178,"zip":179,"country":133,"countryCode":134,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Coral Gables","Florida","33134",{"type":136,"coordinates":181},[182,183],-80.26838,25.72149,{"lat":183,"lon":182},[186,187,188],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":189,"role":148,"phone":21,"phoneExt":21,"email":21},"Ivo Alonso",{"facility":128,"status":129,"city":191,"state":178,"zip":192,"country":133,"countryCode":134,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Miami Lakes","33014",{"type":136,"coordinates":194},[195,196],-80.30866,25.90871,{"lat":196,"lon":195},[199,200,201],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":202,"role":148,"phone":21,"phoneExt":21,"email":21},"Angel Rico",{"facility":128,"status":129,"city":204,"state":178,"zip":205,"country":133,"countryCode":134,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Tampa","33612",{"type":136,"coordinates":207},[208,209],-82.45843,27.94752,{"lat":209,"lon":208},[212,213,214],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":215,"role":148,"phone":21,"phoneExt":21,"email":21},"Michele Johnson Towson",{"facility":128,"status":129,"city":217,"state":218,"zip":219,"country":133,"countryCode":134,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"Idaho Falls","Idaho","83404",{"type":136,"coordinates":221},[222,223],-112.03414,43.46658,{"lat":223,"lon":222},[226,227,228],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":229,"role":148,"phone":21,"phoneExt":21,"email":21},"Boyd Southwick",{"facility":128,"status":129,"city":231,"state":232,"zip":233,"country":133,"countryCode":134,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"Dayton","Ohio","45414",{"type":136,"coordinates":235},[236,237],-84.19161,39.75895,{"lat":237,"lon":236},[240,241,242],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":243,"role":148,"phone":21,"phoneExt":21,"email":21},"Julie Shepard",{"facility":128,"status":129,"city":245,"state":246,"zip":247,"country":133,"countryCode":134,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Houston","Texas","77584",{"type":136,"coordinates":249},[250,251],-95.36327,29.76328,{"lat":251,"lon":250},[254,255,256],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":257,"role":148,"phone":21,"phoneExt":21,"email":21},"Yvette Poindexter",{"facility":128,"status":129,"city":259,"state":246,"zip":260,"country":133,"countryCode":134,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"Lewisville","75067",{"type":136,"coordinates":262},[263,264],-96.99417,33.04623,{"lat":264,"lon":263},[267,268,269],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":270,"role":148,"phone":21,"phoneExt":21,"email":21},"Asgar Dudhbhai",{"facility":128,"status":129,"city":272,"state":246,"zip":273,"country":133,"countryCode":134,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"Mansfield","76063",{"type":136,"coordinates":275},[276,277],-97.14168,32.56319,{"lat":277,"lon":276},[280,281,282],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":283,"role":148,"phone":21,"phoneExt":21,"email":21},"Keithlee Dolinta",{"facility":128,"status":129,"city":285,"state":246,"zip":286,"country":133,"countryCode":134,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"Pharr","78577",{"type":136,"coordinates":288},[289,290],-98.18362,26.1948,{"lat":290,"lon":289},[293,294,295],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":296,"role":148,"phone":21,"phoneExt":21,"email":21},"Belinda Jordan",{"facility":128,"status":129,"city":298,"state":299,"zip":300,"country":133,"countryCode":134,"cosmosGeoPoint":301,"geoPoint":305,"contacts":306},"Richmond","Virginia","23294",{"type":136,"coordinates":302},[303,304],-77.46026,37.55376,{"lat":304,"lon":303},[307,308,309],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":310,"role":148,"phone":21,"phoneExt":21,"email":21},"John Scott",{"facility":128,"status":129,"city":312,"state":21,"zip":313,"country":314,"countryCode":315,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"Alken","3570","Belgium","BE",{"type":136,"coordinates":317},[318,319],5.30558,50.87553,{"lat":319,"lon":318},[322,323,324],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":325,"role":148,"phone":21,"phoneExt":21,"email":21},"Hilde Bollen",{"facility":128,"status":129,"city":327,"state":21,"zip":328,"country":329,"countryCode":330,"cosmosGeoPoint":331,"geoPoint":335,"contacts":336},"Tartu","50106","Estonia","EE",{"type":136,"coordinates":332},[333,334],26.72509,58.38062,{"lat":334,"lon":333},[337,338,339],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":340,"role":148,"phone":21,"phoneExt":21,"email":21},"Airi Põder",{"facility":128,"status":342,"city":343,"state":21,"zip":344,"country":345,"countryCode":346,"cosmosGeoPoint":347,"geoPoint":351,"contacts":21},"WITHDRAWN","Athens","115 27","Greece","GR",{"type":136,"coordinates":348},[349,350],23.72784,37.98376,{"lat":350,"lon":349},{"facility":128,"status":129,"city":343,"state":21,"zip":353,"country":345,"countryCode":346,"cosmosGeoPoint":354,"geoPoint":356,"contacts":357},"11527",{"type":136,"coordinates":355},[349,350],{"lat":350,"lon":349},[358,359,360],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":361,"role":148,"phone":21,"phoneExt":21,"email":21},"Maria Tsolia",{"facility":128,"status":129,"city":363,"state":21,"zip":364,"country":345,"countryCode":346,"cosmosGeoPoint":365,"geoPoint":369,"contacts":370},"Thessaloniki","54642",{"type":136,"coordinates":366},[367,368],22.93493,40.64072,{"lat":368,"lon":367},[371,372,373],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":374,"role":148,"phone":21,"phoneExt":21,"email":21},"Elias Iosifidis",{"facility":128,"status":129,"city":376,"state":21,"zip":377,"country":378,"countryCode":379,"cosmosGeoPoint":380,"geoPoint":384,"contacts":385},"Trzebnica","55-100","Poland","PL",{"type":136,"coordinates":381},[382,383],17.06331,51.31076,{"lat":383,"lon":382},[386,387,388],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":389,"role":148,"phone":21,"phoneExt":21,"email":21},"Henryk Szymanski",{"facility":128,"status":129,"city":391,"state":21,"zip":392,"country":393,"countryCode":394,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Brasov","500283","Romania","RO",{"type":136,"coordinates":396},[397,398],25.60613,45.64861,{"lat":398,"lon":397},[401,402,403],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":404,"role":148,"phone":21,"phoneExt":21,"email":21},"Dana Baraghin",{"facility":128,"status":129,"city":406,"state":21,"zip":407,"country":393,"countryCode":394,"cosmosGeoPoint":408,"geoPoint":412,"contacts":413},"Calarasi","910160",{"type":136,"coordinates":409},[410,411],27.31356,44.2051,{"lat":411,"lon":410},[414,415,416],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":417,"role":148,"phone":21,"phoneExt":21,"email":21},"Alexandra Carmen Cara",{"facility":128,"status":129,"city":419,"state":21,"zip":420,"country":421,"countryCode":422,"cosmosGeoPoint":423,"geoPoint":427,"contacts":428},"Chiang Mai","50200","Thailand","TH",{"type":136,"coordinates":424},[425,426],98.98468,18.79038,{"lat":426,"lon":425},[429,430,431],{"name":119,"role":120,"phone":121,"phoneExt":21,"email":122},{"name":144,"role":120,"phone":145,"phoneExt":21,"email":122},{"name":432,"role":148,"phone":21,"phoneExt":21,"email":21},"Peninnah Oberdorfer",{"type":434,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100581811","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-chickenpox-vaccine-and-a-marketed-measles-mumps-and-rubella-vaccine-when-administered-as-intramuscular-injection-to-healthy-children-12-to-15-months-of-age-100581811",false,"NCT06855160","A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age","Inclusion Criteria:\n\n* Participant's parent(s)\u002F Legally acceptable representatives (LAR\\[s\\]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).\n* Written or witnessed\u002Fthumb printed informed consent obtained from the participant's parent(s)\u002FLAR(s) prior to performance of any study-specific procedure.\n* Healthy participants as established by medical history and clinical examination before entering into the study.\n* A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1-year birthday until the day before 16 months of age) at the time of the administration of study interventions.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions:\n\n  * Participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to the administration of study intervention.\n\nExclusion Criteria:\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions including hypersensitivity to neomycin or gelatin.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* Hypersensitivity to latex.\n* Major congenital defects, as assessed by the investigator.\n* Recurrent history of uncontrolled neurological disorders or seizures.\n* History of measles, mumps, rubella, or varicella disease.\n* Active untreated tuberculosis.\n* Participants with bleeding disorders (e.g., thrombocytopenia or any coagulation disorder).\n* Condition that in the judgment of the investigator would make intramuscular injection unsafe.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.\n\nPrior\u002FConcomitant therapy\n\n* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the dose of study interventions administration (Day -29 to Day 1), or their planned use during the study period.\n* Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune modifying treatments at any time up to the end of the study.\n\n  \\- Up to 90 days prior to the study intervention administration:\n* For corticosteroids, this will mean prednisone equivalent \\>=0.5 mg\u002Fkg\u002Fday with maximum of 20 mg\u002Fday for pediatric participants. Inhaled and topical steroids are allowed.\n* Administration of immunoglobulins and\u002For any blood products or plasma derivatives.\n\n  \\- Up to 180 days prior to study interventions administration: long acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study vaccines, e.g., nirsevimab), antitumoral medication.\n* Previous vaccination against measles, mumps, and rubella.\n* Previous vaccination against varicella virus.\n* Previous vaccination against hepatitis A virus.\n* Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions, participant who previously received a booster dose of any PCV.\n\nPrior\u002FConcurrent clinical study experience\n\n• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug\u002Finvasive medical device).\n\nOther exclusion criteria\n\n* Any study personnel or their immediate dependents, family, or household members.\n* Child in care.\n* Participants with the following high-risk individuals in their household: • Immunocompromised individuals.\n* Pregnant women without documented history of varicella.\n* Newborn infants of mothers without documented history of varicella.\n* Newborn infants born \\\u003C28 weeks of gestation",true,"ALL","12 Months","15 Months",{"count":447,"type":448},911,"ESTIMATED","INTERVENTIONAL",[451],"PHASE3","This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.",[454],"Chickenpox",[456,457,458,459,460],"Chicken pox","Candidate l varicella vaccine (VNS)","Varicella","Varivax","Healthy Children","2026-05-27",{"date":463,"type":464},"2026-05-29","ACTUAL",{"date":466,"type":464},"2025-04-17",{"date":468,"type":448},"2027-02-02",{"name":5,"class":6},22]